<DOC>
	<DOCNO>NCT01772316</DOCNO>
	<brief_summary>This multicenter , open-label , single arm , long-term extension study evaluate safety efficacy RoActemra/Actemra ( tocilizumab ) participant moderate severe rheumatoid arthritis complete 97-week WA22762 96-week NA25220 core study . Participants receive RoActemra/Actemra 162 milligram ( mg ) subcutaneously weekly ( participant enter WA22762 ) every two week ( participant enter NA25220 ) 96 week , telephone call follow-up visit Weeks 100 104 .</brief_summary>
	<brief_title>A Long-Term Extension Study WA22763 NA25220 Subcutaneous RoActemra/Actemra ( Tocilizumab ) Patients With Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult participant , &gt; /= 18 year age Participants complete 97week WA22762 96week NA25220 core study subcutaneous intravenous RoActemra/Actemra base investigator 's judgment may continue benefit RoActemra/Actemra treatment study investigate subcutaneous formulation Oral corticosteroid nonsteroidal antiinflammatory drug ( NSAIDS ) maximum recommend dose permit stable dose regimen &gt; /= 4 week prior baseline Permitted nonbiological diseasemodifying antirheumatic drug ( DMARDs ) allow Receiving treatment outpatient basis Females childbearing potential male female partner childbearing potential must agree use reliable mean contraception Participants prematurely withdraw WA22762 NA25220 core study reason Previous treatment celldepleting therapy , include investigational agent approve therapy History severe allergic anaphylactic reaction human , humanized mural monoclonal antibody Evidence serious uncontrolled concomitant disease Current liver disease determine principal investigator History diverticulitis , diverticulosis require antibiotic treatment chronic ulcerative low gastrointestinal ( GI ) disease Crohn 's disease , ulcerative colitis symptomatic low GI condition might predispose perforation Known active current history recurrent infection Any major episode infection require hospitalization treatment intravenous ( IV ) antibiotic within 4 week screen oral antibiotic within 2 week prior screen Active tuberculosis require treatment within previous 3 year Primary secondary immunodeficiency ( history currently active ) Pregnant breast feed woman Body weight &gt; 150 kilogram ( kg ) Inadequate renal , hepatic hematologic function Positive hepatitis B hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>